Back

Clinical and genetic determinants of adverse outcomes in pediatric biventricular noncompaction

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Paediatric cardiomyopathy Ventricular Noncompaction ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Keiichi Hirono

University of Toyama, Toyama (Japan)

6 More presentations in this session

Presentation thumbnail
Interim results from MyCLIMB, a natural history study of pediatric MYBPC3-associated hypertrophic cardiomyopathy
Doctor G. Sarquella Brugada (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Independent predictors of dismal and favourable outcome in adult and paediatric myocarditis: data from the multicentric Italian Rare Biopsy-proven Myocarditis Registry
Doctor A. Giordani (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Analysis of risk factors and construction of predictive model for adverse outcomes of fulminant myocarditis in children
Professor B. Han (Jinan, CN)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics of genetic and gene-elusive arrhythmogenic cardiomyopathy phenotypes in children.
Doctor S. Moscatelli (London, GB)
Abstract Slides Video
Presentation thumbnail
The yield of clinical screening in childhood relatives of individuals with gene-elusive hypertrophic cardiomyopathy
Doctor G. Norrish (London, GB) Professor J. Kaski (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Paediatric cardiomyopathy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Left ventricular non compaction in sub-saharan african adults
thumbnail
Congress Presentation
Sarcomere gene variants did not improve cardiac function in pediatric patients with dilated cardiomyopathy
thumbnail
Congress Presentation
Characterisation of the novel SCN5A-P1891A variant, implicated in left ventricular noncompaction cardiomyopathy in a Finnish family, using human induced pluripotent stem cell-derived cardiomyocytes.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources